» Articles » PMID: 20040314

Enzyme Replacement Therapy for the Management of the Mucopolysaccharidoses

Overview
Specialty Pharmacology
Date 2009 Dec 31
PMID 20040314
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Enzyme replacement therapy (ERT) is now available for several of the mucopolysaccharidosis disorders. This brief review summarizes the role of ERT in reducing the burden of peripheral disease in many patients with mucopolysaccharidosis disorders, and describes the challenges that remain in treating the neurological manifestations of these conditions.

Citing Articles

A selective screening program for the early detection of mucopolysaccharidosis: Results of the FIND project - a 2-year follow-up study.

Colon C, Alvarez J, Castano C, Gutierrez-Solana L, Marquez A, OCallaghan M Medicine (Baltimore). 2017; 96(19):e6887.

PMID: 28489793 PMC: 5428627. DOI: 10.1097/MD.0000000000006887.


NDST1 Preferred Promoter Confirmation and Identification of Corresponding Transcriptional Inhibitors as Substrate Reduction Agents for Multiple Mucopolysaccharidosis Disorders.

Tkachyova I, Fan X, Lamhonwah A, Fedyshyn B, Tein I, Mahuran D PLoS One. 2016; 11(9):e0162145.

PMID: 27657498 PMC: 5033324. DOI: 10.1371/journal.pone.0162145.


Pain: a prevalent feature in patients with mucopolysaccharidosis. Results of a cross-sectional national survey.

Brands M, Gungor D, van den Hout J, Karstens F, Oussoren E, Plug I J Inherit Metab Dis. 2014; 38(2):323-31.

PMID: 25048386 DOI: 10.1007/s10545-014-9737-0.


Newborn screening and diagnosis of mucopolysaccharidoses.

Tomatsu S, Fujii T, Fukushi M, Oguma T, Shimada T, Maeda M Mol Genet Metab. 2013; 110(1-2):42-53.

PMID: 23860310 PMC: 4047214. DOI: 10.1016/j.ymgme.2013.06.007.


Plasmatic kinetics of dermatan sulfate during enzyme replacement therapy with iduronate-2-sulfatase in a mucopolysaccharidosis II patient.

Volpi N, Zampini L, Maccari F, Santoro L, Galeotti F, Galeazzi T Glycoconj J. 2013; 30(7):727-32.

PMID: 23512580 DOI: 10.1007/s10719-013-9471-0.